Compare Ginkgo Bioworks Holdings Inc (DNA) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Li Auto Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while Li Auto Inc trades at $11.53 (market cap $10.71B). The key difference: Li Auto Inc is far larger — about 14× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Li Auto Inc for 101 Days on average.
| DNA | LI | |
|---|---|---|
Market Cap | $763.64M | $10.71B |
Volume | 3,204,177 | 1,781,143 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $23.61 |
52-Week Low | $5.48 | $10.69 |
Typical Hold Time | 7 Days | 101 Days |
Enterprise Value | $865.59M | $139.58M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
Li Auto (LI) trades at $11.54, down 5.0% recently and near 52-week lows amid weak delivery numbers. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal declining revenue from $144.5B in 2024 to $112.3B in 2025 and negative net income margins. Recent news highlights September deliveries of 31,817 vehicles and new model launches like the Li i9 SUV.
Outlook remains challenging with intense EV competition and cash flow concerns, though analyst consensus suggests 32% upside to $15.18 target. Key risks include execution on new models and Chinese market volatility, while the strong balance sheet provides some stability for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
